Axsome Therapeutics : to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience - Form 8-K

Axsome Therapeutics, Inc. , a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that the Company has entered into a... | March 28, 2022

Related Keywords

China ,New York ,United States ,Japan ,Herriot Tabuteau ,Mark Jacobson ,Bruce Cozadd ,Sk Biopharmaceuticals Co Ltd ,Axsome Therapeutics Inc ,Jazz Pharmaceuticals ,Drug Administration ,Continuous Positive Airway Pressure ,Nasdaq ,European Medicines Agency ,Us Drug Enforcement Agency On ,Airway Pressure ,Hercules Capital Inc ,Symphony Health ,Axsome Therapeutics ,Acquire Sunosi ,Expanding Axsome ,Digital Centric Commercialization ,Chief Executive Officer ,High Potential Commercial Asset ,Late Stage Neuroscience Portfolio ,Therapeutic Focus ,First In Class Digital Centric Commercialization ,Deliver Substantial Shareholder Value ,Aerial Biopharma ,Hercules Capital ,Hart Scott Rodino Antitrust Improvements Act ,United Statestransaction ,Enforcement Agency ,Obstructive Sleep Apnea ,Excessive Daytime Sleepiness ,Sleep Medicine ,Nc Stock Exchange ,News ,Information ,Press Release ,Axsome ,Iopharmaceutical ,Company ,Developing ,Novel ,Therapies ,Or ,The ,Management ,F ,Central ,Nervous ,System ,Oday ,Nnounced ,Hat ,Gas ,Ntered ,Nto Axsm Us05464t1043 ,